Acne Vulgaris, Influence, Probiotic, Serum Leucine-Rich Alpha-2 Glycoprotein 1
Conditions
Brief summary
This study aimed to assess the serum level of Leucine-rich alpha-2 glycoprotein 1 (LRG1) in Acne vulgaris (AV) individuals and evaluate the effect of probiotic therapy on these serum levels.
Detailed description
Acne vulgaris (AV) is a common inflammatory disorder of the pilosebaceous units, characterized by the presence of inflammatory, non-inflammatory, or a combination of both types of lesions. Recent attention has turned toward biomarkers that reflect the inflammatory activity in acne and might act as indicators of disease severity, treatment response, or prognostic risk. One such candidate is Leucine-rich alpha-2 glycoprotein 1 (LRG1). Probiotics are live microorganisms that, when administered in sufficient quantities, can modulate the composition of the gut microbiota, helping reduce microbial dysbiosis, regulate the immune response, and decrease inflammatory mediators, thereby reducing systemic inflammatory burden, which is called the gut-skin-axis relationship.
Interventions
DIAGNOSTIC_TESTSerum Leucine-rich alpha-2 glycoprotein 1 (LRG1) level
Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) levels were assessed in acne vulgaris participants and healthy controls.
Sponsors
Benha University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years. * Both sexes. * Had not used systemic or topical acne therapy for at least two months or two weeks before the research, respectively. * Participants with clinically diagnosed mild to moderate acne vulgaris (AV) based on the Global Acne Grading System (GAGS)
Exclusion criteria
* Pregnancy. * Lactation. * History of hypersensitivity to probiotic components. * Smoking. * Presence of infections. * Autoimmune or malignant diseases. * Receiving any systemic therapy likely to affect the microbiome or inflammatory biomarkers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum Leucine-Rich Alpha-2 Glycoprotein 1 Level | 12 weeks after the therapy | Serum Leucine-Rich Alpha-2 Glycoprotein 1 Level was assessed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Acne severity | 12 weeks after the therapy | Acne severity was assessed based on Global Acne Grading System (GASA) score is considered as 1-18 mild, 19-30 moderate, 31-38 severe, and \>39 very severe |
| Patient satisfaction | 12 weeks after the therapy | Patient satisfaction was evaluated using the Likert scale, with response options ranging from 1 = very dissatisfied to 5 = very satisfied. |
Countries
Egypt
Outcome results
None listed